GENFLEET-B(02595) intends to discount approximately 9.71% to issue 13.6 million shares, raising approximately HK$467 million.

GENFLEET-B (02595) announced that on July 14, 2026 (after trading hours), the company entered into a placing agreement with the placing agent. According to this agreement, the placing agent has agreed to act as the company's agent, using their best efforts to ensure that at least six underwriters subscribe to purchase 13.6 million new H shares at a placing price of HK$34.69 per share. The placing shares represent approximately 4.02% of the H shares issued as of the announcement date, 3.67% of the total issued shares, 3.87% of the H shares issued after the placement, and 3.54% of the total issued shares (assuming no changes to the total issued shares from the announcement date to the settlement date). The total face value of the placing shares will be RMB 136 million. The placing price of HK$34.69 per share was determined through fair negotiation between the company and the placing agent. This price represents a discount of approximately 9.71% from (i) the closing price of H shares on the Stock Exchange of Hong Kong on July 14, 2026 (the date of the placing agreement) of HK$38.42 per share, and approximately 3.49% discount from (ii) the average closing price of H shares on the Stock Exchange of Hong Kong in the five consecutive trading days before the placing agreement date of HK$35.94 per share. Assuming all 13.6 million placing shares are fully subscribed, the total amount raised at settlement will be HK$4.72 billion, with an estimated net amount of HK$4.67 billion after deducting placing commissions and other related expenses. Based on this, the net issue price per placing share will be approximately HK$34.33. The net proceeds from the placing are intended to be used as follows: (1) approximately 75% for advancing core product RAS inhibitors and other innovative therapies (including GFH276, GFS202A, and GFS784); (2) approximately 15% to enhance the company's research and development technology platform; (3) approximately 10% for supplementing working capital and other general corporate purposes.